Prevalence and significance of MEFV gene mutations in a cohort of patients with rheumatoid arthritis

dc.contributor.authorKoca, Suleyman Serdar
dc.contributor.authorEtem, Ebru Onalan
dc.contributor.authorIsik, Bahar
dc.contributor.authorYuce, Huseyin
dc.contributor.authorOzgen, Metin
dc.contributor.authorDag, Muhammet Sait
dc.contributor.authorIsik, Ahmet
dc.date.accessioned2026-08-12T17:45:55Z
dc.date.issued2010
dc.departmentFırat Üniversitesi
dc.description.abstractObjectives: Pyrin/marenostrin, an inhibitory regulator of inflammation, is encoded by MEditerranean FeVer ( MEFV) gene. Mutations of this gene are the cause of familial Mediterranean fever (FMF). A connection between MEFV gene mutations and rheumatic diseases has been suggested. The aim of this study was to explore the frequency and clinical significance of MEFV gene mutations in a cohort of Turkish patients with rheumatoid arthritis ( RA). Methods: The study included 103 patients with RA and 103 age-, sex- and origin-matched healthy controls (HC). In all participants, genomic DNA was isolated and genotyped using amplification refractory mutation system or restriction fragment length polymorphism for the eight MEFV gene mutations (E148Q, M694V, M694I, M680I, V726A, A744S, R761H, and P369S). In the RA group, disease activity was determined using the disease activity score-28 (DAS-28), and radiological damage was evaluated by the modified Larsen scoring method. Results: Carrier rates of MEFV gene mutations were 26/103 (25.2%) and 24/103 (23.3%) in the RA and HC groups, respectively (p > 0.05, OR: 0.9, 95% CI: 0.48 - 1.71). In the RA group, while deformed joint count was significantly higher in the mutation carrier group than those of the non-carrier group ( p < 0.05), the level of C-reactive protein, DAS-28 and modified-Larsen scores were slightly but not significantly higher in the carrier group. Conclusion: The results of this study suggest that MEFV gene mutations appear to be an aggravating factor for the severity of RA, and consequently, patients with RA might be screened for MEFV gene mutations in countries where FMF is frequent. Whether the searching of MEFV gene mutations in RA patients is cost-effective deserves further investigations. (C) 2009 Societe francaise de rhumatologie. Published by Elsevier Masson SAS. All rights reserved.
dc.identifier.doi10.1016/j.jbspin.2009.08.006
dc.identifier.endpage35
dc.identifier.issn1297-319X
dc.identifier.issue1
dc.identifier.orcid0000-0003-4995-430X
dc.identifier.pmid20031469
dc.identifier.scopus2-s2.0-73449102470
dc.identifier.scopusqualityQ2
dc.identifier.startpage32
dc.identifier.urihttps://doi.org/10.1016/j.jbspin.2009.08.006
dc.identifier.urihttps://hdl.handle.net/11508/60870
dc.identifier.volume77
dc.identifier.wosWOS:000273887400007
dc.identifier.wosqualityQ1
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakScopus
dc.indekslendigikaynakPubMed
dc.language.isoen
dc.publisherElsevier France-Editions Scientifiques Medicales Elsevier
dc.relation.ispartofJoint Bone Spine
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanı
dc.rightsinfo:eu-repo/semantics/closedAccess
dc.snmzKA_WoS_20260511
dc.subjectRheumatoid arthritis
dc.subjectMEFV gene mutations
dc.subjectFamilial Mediterranean fever
dc.titlePrevalence and significance of MEFV gene mutations in a cohort of patients with rheumatoid arthritis
dc.typeArticle

Dosyalar